CRISPR Rapidx™ Gene Knockout Kit (Comprehensive)
$3,248.00 - $5,698.00
$8,140.00
All products have special prices for bulk purchase, please contact for more details if required.
Cat. No.: CRGKOC-5 (for 5rxn)
Cat. No.: CRGKOC-10 (for 10rxn)
Cat. No.: CRGKOC-25 (for 25rxn)
Description
CRISPR Rapidx™ Gene Knockout Kit is a ready-to-use, research-grade CRISPR knockout kit. This product includes our innovatively developed CRISPR Rapidx™ Transfection Reagent and Cas enzymes, which have been validated in thousands of practical applications, providing researchers with a rapid and efficient gene knockout tool.
The CRISPR Rapidx™ Transfection Reagent is a biomolecule-assisted delivery system for Cas proteins and gRNA. This transfection reagent is non-toxic to cells and can successfully transfect the Cas-gRNA complex into cells after just 30 minutes of incubation, enabling robust gene editing capabilities.
Advantages
- Efficient Transfection: Employing the innovatively developed CRISPR Rapidx™ Transfection Reagent, transfection takes just 30 minutes, with editing efficiency detectable within 48 hours.
- High Editing Efficiency: With the combination of the efficient transfection reagent, market-validated Cas enzymes, and unique gRNA design logic, knockout efficiency reaches up to 95%.
- Low Cytotoxicity: Biomolecule-assisted delivery of the Cas-gRNA system ensures rapid DNA release and degradation upon cell entry, resulting in minimal cytotoxicity.
- Broad Applicability: Suitable for most cell types, with particular advantages for difficult-to-transfect cells and those with limited growth potential.
- Minimal Equipment Requirements: Achieve high-efficiency editing without the need for instruments such as electroporators, thanks to biomolecule-assisted delivery.
Components
5rxn
- CRISPR Rapidx™ Transfection Reagent: 30μL*5
- Cas12a Nuclease (100μM): 20μL
- crRNA (1.5nmol，dilute to 100μM): 20-30μL
- DNA Lysis:
- Buffer A: 1mL
- Buffer B: 20μL
- PCR Validation:
- 2 x High Fidelity Pfu Mix (+Dye): 300μL
- Genotyping Primer F: 20μL
- Genotyping Primer R: 20μL
10rxn
- CRISPR Rapidx™ Transfection Reagent: 30μL*10
- Cas12a Nuclease (100μM): 40μL
- crRNA (1.5nmol，dilute to 100μM): 40-60μL
- DNA Lysis:
- Buffer A: 2mL
- Buffer B: 40μL
- PCR Validation:
- 2 x High Fidelity Pfu Mix (+Dye): 600μL
- Genotyping Primer F: 40μL
- Genotyping Primer R: 40μL
25rxn
- CRISPR Rapidx™ Transfection Reagent: 30μL*25
- Cas12a Nuclease (100μM): 100μL
- crRNA (1.5nmol，dilute to 100μM): 100-150μL
- DNA Lysis:
- Buffer A: 5mL
- Buffer B: 100μL
- PCR Validation:
- 2 x High Fidelity Pfu Mix (+Dye): 1500μL
- Genotyping Primer F: 100μL
- Genotyping Primer R: 100μL
Comparison of Common Knockout Methods
Storage
Validity: 1 year. Storage conditions: -20°C. For prolonged storage, it is advisable to keep at -80°C. Dry ice transportation is recommended. It's suggested to aliquot based on usage to prevent repeated freeze-thaw cycles.
Q&A
Q1: Why Adopt Cas12a Instead of Cas9?
A1: Our research and development team initially chose Cas12a to reduce costs, as its crRNA is only 40 base pairs long, making it easier and cheaper to synthesize. In our experiments, we paired a specially modified Cas12a with our proprietary CRISPR Rapidx™ Transfection Reagent. During testing, we found that Cas12a's knockout efficiency was significantly higher than Cas9's, especially in hard-to-transfect cells. This combination demonstrated powerful gene knockout capabilities.
Q2: Why Does This Product Cause Minimal Cell Damage?
A2: This product employs our innovatively developed CRISPR Rapidx™ Transfection Reagent. As a biomolecule, this reagent avoids the toxicity common with chemical transfection methods and the cell damage often caused by electroporation. In all the cells we tested, it consistently demonstrated outstanding transfection capabilities.
SBS Genetech is recognized as one of the global major leading industry players in Gene Editing by third-party market researchers. For more details, please visit Global Gene Editing Service Market 2019 by Company, Regions, Type and Application, Forecast to 2024.
Related:
